OncoMatch/Clinical Trials/NCT06492304
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
Is NCT06492304 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CTX131 for t cell lymphoma.
Treatment: CTX131 — This is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Biomarker criteria
Required: MYC rearrangement
high-grade BCL with MYC and BCL2 and/or BCL6 rearrangements
Required: BCL2 rearrangement
high-grade BCL with MYC and BCL2 and/or BCL6 rearrangements
Required: BCL6 rearrangement
high-grade BCL with MYC and BCL2 and/or BCL6 rearrangements
Excluded: BCR BCR-ABL positive
BCR-ABL positive leukemia...are excluded
Disease stage
Required: Stage ≥IIB
Stage ≥IIB Mycosis fungoides (MF)/ Sézary syndrome (SS)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
Stage ≥IIB Mycosis fungoides (MF)/ Sézary syndrome (SS) after at least 2 prior systemic therapies
Must have received: any
Peripheral T cell lymphoma (PTCL) after at least 1 prior line of therapy
Must have received: any
ALK+ Anaplastic large cell lymphoma (ALCL) after at least 2 prior lines of therapy
Must have received: any
ALK- ALCL after at least 1 prior line of therapy
Must have received: anti-CD20 monoclonal antibody
B cell lymphoma...after at least 2 prior lines of therapy including an anti- CD20 monoclonal antibody and an anthracycline containing regimen
Must have received: anthracycline
B cell lymphoma...after at least 2 prior lines of therapy including an anti- CD20 monoclonal antibody and an anthracycline containing regimen
Must have received: anthracycline or bendamustine
Mantle cell lymphoma (MCL) after up to 5 prior lines of therapy which must include an anthracycline- or bendamustine-containing regimen, an anti- CD20 monoclonal antibody, and a BTK inhibitor
Must have received: BTK inhibitor
Mantle cell lymphoma (MCL) after up to 5 prior lines of therapy which must include an anthracycline- or bendamustine-containing regimen, an anti- CD20 monoclonal antibody, and a BTK inhibitor
Must have received: AML therapy
Acute myeloid leukemia or AML/MDS per ELN criteria 2022 after at least 1 prior line of AML therapy
Cannot have received: anti-CD70 targeting agent
Prior treatment with anti-CD70 targeting agents
Cannot have received: anticancer biologic (mogamulizumab)
Concurrent systemic treatment with an anticancer biologic (e.g., monoclonal antibody) within 30 days prior to CTX131 infusion... Mogamulizumab treatment is prohibited 50 days prior to CTX131 infusion.
Cannot have received: non-biological anticancer drug
Concurrent systemic treatment...with a non-biological anticancer drug within 14 days prior to CTX131 infusion
Cannot have received: CD19-targeting CAR-T
Treatment with CD19-targeting CAR-T within 6 months prior to CTX131 infusion
Lab requirements
Kidney function
Liver function
Cardiac function
Adequate renal, liver, cardiac and pulmonary organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site 6 · Phoenix, Arizona
- Research Site 5 · Stanford, California
- Research Site 3 · Boston, Massachusetts
- Research Site 4 · New York, New York
- Research Site 2 · The Bronx, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify